Visus presbyopia drop gets FDA IND OK

, ,

A presbyopia-correcting eyedrop recently received FDA acceptance of its investigational new drug (IND) application

Rhett Schiffman, MD, MHSA, chief medical officer and head of research and development at Visus Therapeutics, talks with Gretchyn Bailey, NCLC, FAAO, editor in chief of Optometry Times® about Brimichol, the company’s presbyopia-correcting eyedrop that recently received FDA acceptance of its investigational new drug (IND) application.